In the United States, on May 26, 2026, an FDA advisory panel recommended updating Covid vaccines to address the emerging XFG variant, which is gaining traction among new infections. This recommendation from the FDA’s Vaccines and Related Biological Products Advisory Committee aims to prepare vaccine manufacturers for potential increases in Covid cases as fall and winter approach, historically associated with higher infection rates. XFG is a hybrid strain of two omicron variants, showing mutations that may help it evade immunity developed from prior infections or vaccinations. As of May 8, this variant accounted for more than half of new infections, making it the dominant strain. During the panel meeting, data presented by Moderna and Novavax indicated that vaccines focusing on XFG generate higher antibody levels against circulating strains compared to existing formulations. Pfizer’s data suggested similar antibody levels for both the XFG-targeted and current formulations. Despite the potential benefits of the updated vaccines, one committee member abstained from voting due to concerns that the data supporting the XFG vaccine was not significantly more convincing. The outcome of the committee's vote is still pending further review by the FDA. Given that Covid activity remains at a medium level across the United States and that newer variants like XFG continue to evolve, the recommendation serves as a proactive step to address the ongoing public health challenge. Experts are currently analyzing whether these newer variants will lead to more severe symptoms or transmissibility. Overall, the quick evolution of the virus highlights the importance of continuous monitoring and the need for vaccines to adapt, reflecting a shift in the landscape of Covid-19 in the country.